Retatrutide is encountered primarily in regulated clinical trial settings
As of March 2026, two trials are actively recruiting new participants: the Maintenance trial (NCT06859268, testing dose reduction after initial weight loss) and a new enrollment trial (NCT07232719, 250 participants with obesity or overweight)
doi: 10.4178/epih.e2019013 13 ChaimaniAHigginsJPMavridisDSpyridonosPSalantiG
A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
The preclinical side effect profile is favorable over 4 weeks: no pathological cardiac hypertrophy (some ERRalpha myocardial effects are physiological, dose is calibrated to remain in the adaptive range), no hepatic toxicity, no mitogenic signal at tested doses
The combination of diet, exercise and GLP-1 therapies enhances weight loss, improves body composition, reduces visceral fat and inflammation, and may confer longer-term benefits in slowing weight regain
